Moreover, agents which can selectively block dual targets, namely PD-L1 and PD-L2, have been intended to be developed for the treatment of a variety of advanced solid tumors, based on the fact that inhibition of PD-L2 can restore the ability of the immune system to recognize and kill cancer cells [106,107]. This evidence concerns the gene CD274 and cancer.